Biotek-snakken — Januar 2024
-
Could CRISPR Therapeutics Stock Help You Become a Millionaire? https://www.proinvestor.com/investornyt/1106077/could-crispr-therapeutics-stock-help-you-become-a-millionaire
-
"The subscription price of SEK 0.23 per share corresponds to a discount of approximately 39.0 percent compared to the theoretical price after separation of unit rights, based on the closing price of Xbrane’s share on Nasdaq Stockholm on 19 January 2024, the last trading day before announcement of the Rights Issue."
-
Calliditas Therapeutics: Pioneering New Treatments for Rare Diseases (JANUARY 2024)
-
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
-
"The substantial increase from 2022 revenue of RMB12.8 million was mainly due to Xerava
's successful commercial launch in July 2023 and Nefecon's commercial launch in Macau in December 2023. This is also significantly higher than our previous 2023 revenue guidance of RMB70 to 100 million." -
"We will be launching Nefecon
soon in China, making this first-in-disease medicine available to 5 million IgAN patient in the country. We expect 2024 revenue to grow significantly from 2023, and would like to reaffirm our 2024 revenue guidance of RMB700 million."
X-Brane-Evaxion-Genmab alle øv har alle og alt for mange aktier i dem så er lidt nede humørmæssigt men god dag til alle Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind